Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis

doi:10.21037/apm-22-690

HFCAS OpenIR

	Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis
	Lei, Lei 1; Chen, Rucheng 2; Fan, Lei 3; Zheng, Weijun 2; Wang, Xiaojia 1
	2022-07-01
发表期刊	ANNALS OF PALLIATIVE MEDICINE
ISSN	2224-5820
通讯作者	Wang, Xiaojia(wxiaojia0803@163.com)
摘要	Background: Long-term benefit of nanoparticle-albumin-bound paclitaxel (Nab-P) over conventional taxanes in breast cancer patients is still controversial. We conducted a systematic review of studies to identify the optimal taxanes for selection in dinical practice. Methods: We enrolled studies if they enrolled adults (age 18) with breast cancer, compared Nab-P (at any dose) to conventional paclitaxel or docetaxel, provided information on survival data, the response rate, or adverse events, were randomized controlled trials, case-control studies, or cohort studies, and were published in English (including those published online, ahead of the print publication). Cochrane Collaboration tool and Newcastle-Ottawa scale were used for bias-risk assessment. Grading of recommendations assessment, development, and evaluation approach were adopted for the quality of evidence evaluation. The outcomes included the overall response rate, pathological complete response rate, progression-free survival, overall survival, allergic reaction, leukopenia, neutropenia, and sensory neuropathy. Results: A total of 20 eligible clinical studies comprising 11,046 patients were included in the analysis. No significant publication bias was observed based on a visual inspection of the funnel plots for progression-free survival (PFS), and overall survival (OS). Compared to the conventional taxanes group (n=2,743), the Nab-P group (n=1,680) had a significantly higher ORR (RR =1.21, 95% CI: 1.07-1.37; P=0.003) and pCR (RR =1.33, 95% CI: 1.17-1.51; P<0.001). The Nab-P group also had a lower risk of disease progression and death than the conventional taxanes group (HR =0.89, P=0.269). Additionally, the Nab-P group had fewer treatment-related allergic reactions (RR =0.74, 95% CI: 0.59-0.93; P=0.009) and less grade neutropenia (RR =0.39, 95% CI: 0.20-0.77; P=0.007) than the conventional taxanes group. The incidence of any-grade of >= 4 neutropenia and sensory neuropathy were significantly higher in the Nab-P group than the conventional taxanes group (P=0.009 and P<0.001, respectively). Discussion: The Nab-P in all stages of breast cancer patients had significantly better efficacy and tolerance than the conventional taxanes. Moreover, preventive strategies for reducing the incidence of Nab-P induced sensory neuropathy should be explored in future studies.
关键词	Breast cancer nanoparticle-albumin-bound paclitaxel (Nab-P) taxanes meta-analysis
DOI	10.21037/apm-22-690
关键词[WOS]	SOLVENT-BASED PACLITAXEL ; PHASE-III TRIAL ; NEOADJUVANT NAB-PACLITAXEL ; 1ST-LINE CHEMOTHERAPY ; LOCALLY RECURRENT ; CREMOPHOR-FREE ; THERAPY ; NEUROTOXICITY ; TRASTUZUMAB ; BEVACIZUMAB
收录类别	SCI
语种	英语
资助项目	Wu Jieping Medical Foundation[320675012292] ; Zhejiang Public Welfare Technology Research Program[LGJ20H160001] ; Health General Program of Zhejiang Provinces[2021KY088] ; Zhejiang Traditional Chinese Medicine Science Fund Project[2020ZB037] ; Scientific Research Foundation of Zhejiang Medical Association[2016ZYC-A06]
项目资助者	Wu Jieping Medical Foundation ; Zhejiang Public Welfare Technology Research Program ; Health General Program of Zhejiang Provinces ; Zhejiang Traditional Chinese Medicine Science Fund Project ; Scientific Research Foundation of Zhejiang Medical Association
WOS研究方向	Health Care Sciences & Services
WOS类目	Health Care Sciences & Services
WOS记录号	WOS:000880123300023
出版者	AME PUBLISHING COMPANY
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/130169
专题	中国科学院合肥物质科学研究院
通讯作者	Wang, Xiaojia
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China 2.Zhejiang Chinese Med Univ, Sch Publ Hlth, Hangzhou, Peoples R China 3.Fudan Univ, Dept Breast Surg, Canc Ctr & Canc Inst, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Lei, Lei,Chen, Rucheng,Fan, Lei,et al. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis[J]. ANNALS OF PALLIATIVE MEDICINE,2022,11.
APA	Lei, Lei,Chen, Rucheng,Fan, Lei,Zheng, Weijun,&Wang, Xiaojia.(2022).Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis.ANNALS OF PALLIATIVE MEDICINE,11.
MLA	Lei, Lei,et al."Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis".ANNALS OF PALLIATIVE MEDICINE 11(2022).